SparingVision

Description

SparingVision develops gene-agnostic genomic medicines that target photoreceptors to preserve and restore vision in inherited retinal diseases and other blinding retinal conditions through photoreceptor-targeted gene therapies and clinical development.

SparingVision is located in the Paris ecosystem.

Related

• BraineverBrainever develops hEN1 and hOTX2 homeoprotein drug candidates intended to limit neurodegenerative disease progression by preventing…
• Orchard TherapeuticsOrchard Therapeutics develops and commercializes ex vivo autologous gene therapies that modify a patient’s own cells outside the body and…
• Breye TherapeuticsBreye Therapeutics develops orally administered ophthalmology drugs, including danegaptide and P2X7 receptor antagonists, to treat retinal…
• SpliceBioSpliceBio builds protein splicing–based genetic medicines and develops therapeutics for diseases caused by mutations in large genes,…
• SanofiSanofi develops medicines and vaccines through research and development and AI methods, communicates clinical and patient resources, and…
• LEO PharmaLEO Pharma develops and delivers innovative treatments for medical dermatology, producing medicines and supplying healthcare providers and…
• Agen BioTechAgen BioTech develops pure hyaluronic acid products, medical devices, and regenerative medicine therapies through research and development…
• HAYA TherapeuticsHAYA Therapeutics develops RNA-guided medicines that use functional genomics and computational tools to identify, target, and monitor…
• Hansa BiopharmaHansa Biopharma develops immunomodulating antibody-cleaving enzyme therapies that target and inactivate IgG antibodies, inhibiting…